What’s Next After 20 Years Of NICE?
NICE's Growing Importance Has Brought Increasing Scrutiny
Executive Summary
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
You may also be interested in...
Is NICE’s Pricing Influence On The Wane?
The pricing of medicines may appear as a mystery to many; theories range from what the market will bear to prices being based on value. The Pink Sheet examines the role of two key players with influence in drug pricing in the UK – health technology assessment body NICE, which decides whether a product is value for money, and NHS England, which leads the tax-funded national health service in England and pays for new specialized drugs.
C-Suite Snippets: Meindert Boyson's NICE Advice
In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.
Decision On Covid-19 TRIPS Waiver Postponed
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Need a specific report? 1000+ reports available
Buy Reports